Bengaluru, August 31, 2021(FMNews) – A combination therapy of aspirin, statins and at least two blood pressure medications given in fixed doses can slash the risk of fatal cardiovascular disease (CVD) by more than half, says an international study led by researchers in Canada and India.
The fixed-dose combination (FDC) therapies were examined both with and without aspirin versus control groups in a combined analysis of more than 18,000 patients without prior CVD from three large clinical trials. FDCs including aspirin cut the risk of heart attacks by 53 percent, stroke by 51 percent, and deaths from cardiovascular causes by 49 per cent.
The results were welcomed by international leaders in cardiovascular research. Approximately 19 million people worldwide die of CVD and twice as many experience heart attacks or strokes every year.
About 80% of cardiovascular events occur in individuals without a prior history of such illness, meaning effective preventative strategies including medications in people without CVD is essential, if the majority of heart attacks, strokes and related deaths in the world are to be prevented, the authors of the study state.
“This combination, either given separately or combined as a polypill, substantially reduces fatal and non-fatal CVD events,” said lead author Phil Joseph, associate professor of medicine at McMaster University, investigator at the Population Health Research Institute and cardiologist at Hamilton Health Sciences.
“The largest effects are seen with treatments that include blood pressure lowering agents, a statin and aspirin together, which can reduce fatal and non-fatal cardiovascular events by about half.”
“The benefits are consistent at different blood pressure levels, cholesterol levels and with or without diabetes, but larger benefits may occur in older people.”
Joseph is the first author of the meta-analysis study by the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences. Salim Yusuf, executive director of the PHRI and Distinguished University Professor at McMaster, is the senior author and the Principal Investigator.
The study involved investigators from 13 countries and included participants from 26 countries and every inhabited continent of the world. The study was published by The Lancet today and concurrently presented at the European Society of Cardiology Congress by Joseph.
Dr. Xavier said, “We are delighted that this metanalysis of polypill trials has confirmed the efficacy of the polypill. Several physicians and their staff in over 60 hospitals in India worked hard to conduct these research studies. We now hope to work at advocating its inclusion in the county’s health programme”.
“India has a huge burden of young onset type 2 diabetes and premature cardiovascular disease. In India adherence to drug treatments is very poor and therefore a Polypill can help to save millions of lives” said Dr V Mohan leading Diabetologist and Director, Madras Diabetes Research Foundation one of the sites where the study was carried out.”
Dr. PP Mohanan, President of the Cardiology Society of India said, “The phenomenal protection offered by Polypill against cardiovascular disease is a gratifying information. There shouldn’t be a debate on its usefulness now and India with the maximum number of CVD patients is going to benefit most. Let this important information get propagated to every treating clinician across the globe”.
“Heart diseases are the leading cause of death in India and have a huge economic impact both to individuals, families and the nation. Therefore, its prevention is paramount to protect the population and enhance the economic growth of India. The study demonstrates the power of a simple innovation of low-cost fixed dose combination in preventing heart diseases substantially” said Dr. Prabhakaran D, Vice President of the Public Health Foundation of India.